XaTek's ClotChip® technology revolutionizes the clinical evaluation of whole-blood coagulation by utilizing miniaturized dielectric spectroscopy. This innovative approach allows for the analysis of single-drop whole-blood samples, providing both quantitative and qualitative measurements that are crucial for understanding a patient's hemostatic process. By applying an external electric field to the blood sample, ClotChip® measures the impedance within the fluid, which directly correlates to the blood's coagulability. This method is particularly advantageous as it is sensitive to both non-cellular and cellular abnormalities in the coagulation process, enabling clinicians to gain insights into a patient's clotting ability without needing prior knowledge of their medical history or specific reagents.

The accessibility and simplicity of ClotChip® make it a game-changer in point-of-care settings. Unlike traditional global hemostasis assays that require extensive training and specialized equipment, ClotChip® is designed to be user-friendly and widely applicable across various markets. This technology has received FDA breakthrough device designation, highlighting its potential to significantly improve the evaluation and management of bleeding risks. By providing ready access to critical coagulation information at the point of care, ClotChip® aims to enhance patient outcomes for those with blood clotting conditions.

United States

XaTek is a biotechnological company that focuses on developing a portable sensing system that can assess the clotting ability of a person’s blood.

XaTek(ClotChip)

Company Details